Efecto negativo del bloqueo del sistema renina-angiotensina sobre la progresión de la enfermedad renal crónica avanzada: ¿una cuestión de ajuste de dosis?

Nefrología - Tập 40 - Trang 38-45 - 2020
Fernando Caravaca-Fontán1, Julián Valladares1, Rosa Díaz-Campillejo1, Sergio Barroso1, Enrique Luna1, Francisco Caravaca1
1Servicio de Nefrología, Hospital Infanta Cristina, Badajoz, España

Tài liệu tham khảo

Ruggenenti, 2001, ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy, J Am Soc Nephrol., 12, 2832, 10.1681/ASN.V12122832 Remuzzi, 2006, Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes, J Clin Invest., 116, 288, 10.1172/JCI27699 Balamuthusamy, 2008, Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis, Am Heart J., 155, 791, 10.1016/j.ahj.2008.01.031 Ruilope, 2008, Angiotensin receptor blockers: RAAS blockade and renoprotection, Curr Med Res Opin., 24, 1285, 10.1185/030079908X291921 Bakris, 2008, Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression, Postgrad Med., 120, 33, 10.3810/pgm.2008.04.1758 Čertíková Chábová, 2017, The dilemma of dual renin-angiotensin system blockade in chronic kidney disease: why beneficial in animal experiments but not in the clinic?, Physiol Res., 66, 181, 10.33549/physiolres.933607 McMurray, 2003, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial, Lancet., 362, 767, 10.1016/S0140-6736(03)14283-3 Weir, 2007, Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?, Clin Ther., 29, 1803, 10.1016/j.clinthera.2007.09.019 Ravandi, 2009, Blocking the renin-angiotensin system: dual- versus mono-therapy, Expert Rev Cardiovasc Ther., 7, 667, 10.1586/erc.09.47 Cohn, 2001, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure, N Engl J Med., 345, 1667, 10.1056/NEJMoa010713 Epstein, 2009, Recent changes in the landscape of combination RAS blockade, Expert Rev Cardiovasc Ther., 7, 1373, 10.1586/erc.09.127 Pfeffer, 2003, Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both, N Engl J Med., 349, 1893, 10.1056/NEJMoa032292 Yusuf, 2008, Telmisartan, ramipril, or both in patients at high risk for vascular events, N Engl J Med., 358, 1547, 10.1056/NEJMoa0801317 Mann, 2008, Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial, Lancet., 372, 547, 10.1016/S0140-6736(08)61236-2 Suissa, 2006, ACE-inhibitor use and the long-term risk of renal failure in diabetes, Kidney Int., 69, 913, 10.1038/sj.ki.5000159 Griffin, 2006, Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade, Clin J Am Soc Nephrol., 1, 1054, 10.2215/CJN.02231205 Onuigbo, 2008, Late onset azotemia from RAAS blockade in CKD patients with normal renal arteries and no precipitating risk factors, Ren Fail., 30, 73, 10.1080/08860220701742161 Onuigbo, 2008, Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients, Int Urol Nephrol., 40, 233, 10.1007/s11255-007-9299-2 Ahmed, 2010, The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease, Nephrol Dial Transplant., 25, 3977, 10.1093/ndt/gfp511 Onuigbo, 2009, Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution, Nephron Clin Pract., 113, c63, 10.1159/000228536 Tseng, 2017, Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study, Int J Cardiol., 238, 72, 10.1016/j.ijcard.2017.03.080 Oh, 2017, The impact of renin-angiotensin system blockade on renal outcomes and mortality in pre-dialysis patients with advanced chronic kidney disease, PLoS One., 12, e0170874, 10.1371/journal.pone.0170874 Caravaca-Fontán, 2018, Patterns of progression of chronic kidney disease at later stages, Clin Kidney J., 11, 246, 10.1093/ckj/sfx083 Davies, 1995, Comorbidity, urea kinetics, and appetite in continuous ambulatory peritoneal dialysis patients: their interrelationship and prediction of survival, Am J Kidney Dis., 26, 353, 10.1016/0272-6386(95)90657-6 Myers, 2006, Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program, Clin Chem., 52, 5, 10.1373/clinchem.2005.0525144 Levey, 1999, A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group, Ann Intern Med., 130, 461, 10.7326/0003-4819-130-6-199903160-00002 Bhandari, 2016, Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial, Nephrol Dial Transplant., 31, 255 Whaley-Connell, 2012, Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat, Regul Pept., 176, 36, 10.1016/j.regpep.2012.03.002 Moniwa, 2013, Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension, Hypertension., 61, 417, 10.1161/HYPERTENSIONAHA.112.201889 Hoyer, 1993, Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure, Clin Pharmacokinet., 24, 230, 10.2165/00003088-199324030-00005 Sica, 2002, The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease, J Renin Angiotensin Aldosterone Syst., 3, 247, 10.3317/jraas.2002.046